|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2009-11-3
|
|
pubmed:abstractText |
Current intraperitoneal (IP) regimens for the treatment of ovarian cancer rely on cisplatin (DDP) whereas intravenous regimens rely on carboplatin (CBDCA). A major question in the field is whether CBDCA can replace DDP for IP treatment. We compared the uptake of IP administered DDP and CBDCA into human ovarian carcinoma nodules of various sizes growing on the peritoneal surface of nu/nu mice.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1095-6859
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
115
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
362-6
|
|
pubmed:dateRevised |
2011-9-22
|
|
pubmed:meshHeading |
pubmed-meshheading:19775736-Animals,
pubmed-meshheading:19775736-Carboplatin,
pubmed-meshheading:19775736-Cell Line, Tumor,
pubmed-meshheading:19775736-Cisplatin,
pubmed-meshheading:19775736-Cystadenocarcinoma, Serous,
pubmed-meshheading:19775736-Female,
pubmed-meshheading:19775736-Humans,
pubmed-meshheading:19775736-Mice,
pubmed-meshheading:19775736-Mice, Nude,
pubmed-meshheading:19775736-Ovarian Neoplasms,
pubmed-meshheading:19775736-Platinum,
pubmed-meshheading:19775736-Transplantation, Heterologous
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Tumor platinum concentration following intraperitoneal administration of cisplatin versus carboplatin in an ovarian cancer model.
|
|
pubmed:affiliation |
Moores Cancer Center, University of California, San Diego, 3855 Health Sciences Drive, La Jolla, CA 92093-0819, USA. djandial@uci.edu
|
|
pubmed:publicationType |
Journal Article,
Research Support, N.I.H., Extramural
|
